164 related articles for article (PubMed ID: 22563027)
41. Interleukin 2 defect in the peripheral blood and the lung in patients with Sjögren's syndrome.
Miyasaka N; Murota N; Yamaoka K; Sato K; Yamada T; Nishido T; Okuda M
Clin Exp Immunol; 1986 Sep; 65(3):497-505. PubMed ID: 3490935
[TBL] [Abstract][Full Text] [Related]
42. Sjögren's syndrome: cytokine and Epstein-Barr viral gene expression within the conjunctival epithelium.
Jones DT; Monroy D; Ji Z; Atherton SS; Pflugfelder SC
Invest Ophthalmol Vis Sci; 1994 Aug; 35(9):3493-504. PubMed ID: 8056525
[TBL] [Abstract][Full Text] [Related]
43. Phenotypic and functional abnormalities in the peripheral blood T-cells of patients with primary Sjogren's syndrome.
Aziz KE; McCluskey PJ; Wakefield D
Cytometry; 1994 Mar; 18(1):35-41. PubMed ID: 8082485
[TBL] [Abstract][Full Text] [Related]
44. IL-17-producing double-negative T cells are expanded in the peripheral blood, infiltrate the salivary gland and are partially resistant to corticosteroid therapy in patients with Sjögren's syndrome.
Alunno A; Bistoni O; Bartoloni Bocci E; Caterbi S; Bigerna B; Pucciarini A; Tabarrini A; Mannucci R; Beghelli D; Falini B; Gerli R
Reumatismo; 2013 Oct; 65(4):192-8. PubMed ID: 24192564
[TBL] [Abstract][Full Text] [Related]
45. Production of interleukin 2 (IL 2) by salivary gland lymphocytes in Sjögren's syndrome. Detection of reactive cells by using antibody directed to synthetic peptides of IL 2.
Fox RI; Theofilopoulos AN; Altman A
J Immunol; 1985 Nov; 135(5):3109-15. PubMed ID: 3876375
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway.
González-Alvaro I; Ortiz AM; Domínguez-Jiménez C; Aragón-Bodi A; Díaz Sánchez B; Sánchez-Madrid F
Ann Rheum Dis; 2009 Oct; 68(10):1644-50. PubMed ID: 18957484
[TBL] [Abstract][Full Text] [Related]
47. Biochemical deficiency of pyridoxine does not affect interleukin-2 production of lymphocytes from patients with Sjögren's syndrome.
Tovar AR; Gómez E; Bourges H; Ortíz V; Kraus A; Torres N
Eur J Clin Nutr; 2002 Nov; 56(11):1087-93. PubMed ID: 12428174
[TBL] [Abstract][Full Text] [Related]
48. Induction of salivary gland epithelial cell injury in Sjogren's syndrome: in vitro assessment of T cell-derived cytokines and Fas protein expression.
Abu-Helu RF; Dimitriou ID; Kapsogeorgou EK; Moutsopoulos HM; Manoussakis MN
J Autoimmun; 2001 Sep; 17(2):141-53. PubMed ID: 11591123
[TBL] [Abstract][Full Text] [Related]
49. Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study.
van Woerkom JM; Kruize AA; Geenen R; van Roon EN; Goldschmeding R; Verstappen SM; van Roon JA; Bijlsma JW
Ann Rheum Dis; 2007 Aug; 66(8):1026-32. PubMed ID: 17223657
[TBL] [Abstract][Full Text] [Related]
50. Upregulation of interferon-gamma and interleukin-4, Th cell-derived cytokines by So-Shi-Ho-Tang (Sho-Saiko-To) occurs at the level of antigen presenting cells, but not CD4 T cells.
Kang H; Choi TW; Ahn KS; Lee JY; Ham IH; Choi HY; Shim ES; Sohn NW
J Ethnopharmacol; 2009 May; 123(1):6-14. PubMed ID: 19429332
[TBL] [Abstract][Full Text] [Related]
51. Blood mononuclear cells in patients with primary Sjögren's syndrome: production of interleukins, enumeration of interleukin-2 receptors, and DNA synthesis.
Enk C; Oxholm P; Tvede N; Bendtzen K
Scand J Rheumatol Suppl; 1986; 61():131-4. PubMed ID: 3109021
[TBL] [Abstract][Full Text] [Related]
52. CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation.
de Totero D; Tazzari PL; Capaia M; Montera MP; Clavio M; Balleari E; Foa R; Gobbi M
Haematologica; 2003 Feb; 88(2):148-58. PubMed ID: 12604404
[TBL] [Abstract][Full Text] [Related]
53. Additive immunosuppressive effect of leflunomide and hydroxychloroquine supports rationale for combination therapy for Sjögren's syndrome.
van der Heijden EH; Hartgring SA; Kruize AA; Radstake TR; van Roon JA
Expert Rev Clin Immunol; 2019 Jul; 15(7):801-808. PubMed ID: 31192747
[No Abstract] [Full Text] [Related]
54. Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sjögren’s syndrome: a pilot study.
Adler S; Körner M; Förger F; Huscher D; Caversaccio MD; Villiger PM
Arthritis Care Res (Hoboken); 2013 Nov; 65(11):1862-8. PubMed ID: 23740889
[TBL] [Abstract][Full Text] [Related]
55. B Cell Depletion Therapy Normalizes Circulating Follicular Th Cells in Primary Sjögren Syndrome.
Verstappen GM; Kroese FG; Meiners PM; Corneth OB; Huitema MG; Haacke EA; van der Vegt B; Arends S; Vissink A; Bootsma H; Abdulahad WH
J Rheumatol; 2017 Jan; 44(1):49-58. PubMed ID: 28042126
[TBL] [Abstract][Full Text] [Related]
56. Circulating levels of Th1/Th2 cytokines in patients with primary Sjögren's syndrome: correlation with clinical and immunological features.
Garcíc-Carrasco M; Font J; Filella X; Cervera R; Ramos-Casals M; Sisó A; Aymamí A; Ballesta AM; Ingelmo M
Clin Exp Rheumatol; 2001; 19(4):411-5. PubMed ID: 11491496
[TBL] [Abstract][Full Text] [Related]
57. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.
Seror R; Sordet C; Guillevin L; Hachulla E; Masson C; Ittah M; Candon S; Le Guern V; Aouba A; Sibilia J; Gottenberg JE; Mariette X
Ann Rheum Dis; 2007 Mar; 66(3):351-7. PubMed ID: 16950808
[TBL] [Abstract][Full Text] [Related]
58. [Effect of prescriptions replenishing vital essence, tonifying Qi and activating blood on TNF-alpha, IL-1beta expressions in serum and submaxillary gland of NOD mice with Sjogren's syndrome].
Wu GL; Li TY; Pu XH; Yu GY
Zhongguo Zhong Yao Za Zhi; 2013 Feb; 38(3):413-6. PubMed ID: 23668020
[TBL] [Abstract][Full Text] [Related]
59. Clinical and immunological consequences of total glucosides of paeony treatment in Sjögren's syndrome: A randomized controlled pilot trial.
Zhou Y; Jin L; Kong F; Zhang H; Fang X; Chen Z; Wang G; Li X; Li X
Int Immunopharmacol; 2016 Oct; 39():314-319. PubMed ID: 27517517
[TBL] [Abstract][Full Text] [Related]
60. Influence of total glucosides of paeony on PD-1/PD-L1 expression in primary Sjögren's syndrome.
Chen Y; Wang Y; Xu L; Zhu W; Xu C; Xu M; Guo L; Hu W; Xu D; Jing R; Zhu Y; He J; Xu B
Int J Rheum Dis; 2019 Feb; 22(2):200-206. PubMed ID: 30338648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
